PTPN2 and neoplasm: However, PD‐L1 and PTPN2 are not only overexpressed in tumor cells but also exist in other immune cells and tissue cells, which may give rise to undesirable safety issues after systemic administration.[12] Besides, as a targeted nuclease editing toolbox, various delivery obstacles before CRISPR/Cas9 reaching the destination make the dilemma even worse.[13] Therefore, the development of feasible strategy to specifically and efficiently delivery CRISPR/Cas9 to target sites for activation of adaptive immunity has become a priority.